# Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

> **NCT07685938** · PHASE2 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Chest Wall Tumor
- Breast Cancer
- Lung Cancer
- Esophageal Cancer
- Mediastinal Cancers
- Spine Metastases
- Spinal Tumor
- Thoracic Cancer
- Thoracic Neoplasms

## Interventions

- **DRUG:** Atorvastatin and Lisinopril
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07685938
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-12
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685938, "Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07685938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*